A plain language summary of the PHAROS study: The combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer Review
| Authors: | Riely, G. J.; Smit, E. F.; Ahn, M. J.; Felip, E.; Ramalingam, S. S.; Tsao, A.; Johnson, M.; Gelsomino, F.; Esper, R.; Nadal, E.; Offin, M.; Provencio, M.; Clarke, J.; Hussein, M.; Otterson, G. A.; Dagogo-Jack, I.; Goldman, J. W.; Morgensztern, D.; Alcasid, A.; Usari, T.; Wissel, P.; Wilner, K.; Pathan, N.; Tonkovyd, S.; Johnson, B. E. |
| Review Title: | A plain language summary of the PHAROS study: The combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer |
| Abstract: | What is this summary about?: This is a summary of the results of a study called PHAROS. This study looked at combination treatment with encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®). This combination of medicines was studied in people with metastatic non-small-cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. Metastatic means that the cancer has spread to other parts of the body. All people in this study had a type of NSCLC that has a change in a gene called BRAF termed a BRAF V600E mutation. A gene is a part of the DNA that has instructions for making things that your body needs to work, and the BRAF V600E mutation contributes to the growth of the lung cancer. What were the results?: In this study, 98 people with BRAF V600E-mutant metastatic NSCLC were treated with the combination of encorafenib and binimetinib (called encorafenib plus binimetinib in this summary). Before starting the study, 59 people had not received any treatment for their metastatic NSCLC, and 39 people had received previous anticancer treatment. At the time of this analysis, 44 (75%) out of 59 people who did not receive any treatment before taking encorafenib plus binimetinib had their tumors shrink or disappear. Eighteen (46%) out of 39 people who had received treatment before starting encorafenib plus binimetinib also had their tumors shrink or disappear. The most common side effects of encorafenib plus binimetinib were nausea, diarrhea, fatigue, and vomiting. What do the results mean?: These results support the use of encorafenib plus binimetinib combination treatment as a new treatment option in people with BRAF V600E-mutant metastatic NSCLC. The side effects of encorafenib plus binimetinib in this study were similar to the side effects seen with encorafenib plus binimetinib in people with a type of skin cancer called metastatic melanoma. © 2024 The Authors. |
| Keywords: | adult; treatment outcome; aged; aged, 80 and over; middle aged; gene mutation; genetics; mutation; fatigue; cancer growth; diarrhea; outcome assessment; antineoplastic agent; adenocarcinoma; gene; melanoma; metastasis; nausea; vomiting; antineoplastic combined chemotherapy protocols; carcinoma, non-small-cell lung; lung neoplasms; skin cancer; lung cancer; antineoplastic activity; pathology; lung tumor; alanine aminotransferase; aspartate aminotransferase; hospitalization; sulfonamide; sulfonamides; neoplasm metastasis; health care personnel; caregiver; drug therapy; b raf kinase; benzimidazole derivative; benzimidazoles; carbamates; proto-oncogene proteins b-raf; braf protein, human; non-small-cell lung cancer; self care; non small cell lung cancer; metastatic melanoma; phase 2 clinical trial (topic); carbamic acid derivative; dabrafenib; trametinib; very elderly; humans; human; male; female; article; binimetinib; encorafenib; braf v600e gene; plain language summary; encorafenib plus binimetinib; pharos |
| Journal Title: | Future Oncology |
| Volume: | 20 |
| Issue: | 16 |
| ISSN: | 1479-6694 |
| Publisher: | Future Medicine |
| Date Published: | 2024-01-01 |
| Start Page: | 1047 |
| End Page: | 1055 |
| Language: | English |
| DOI: | 10.2217/fon-2023-0859 |
| PUBMED: | 38357801 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work